当前位置:首页>产品中心>单抗/多抗>Anti-Human TACR2 Polyclonal Antibody|抗人TACR2多克隆抗体(靶标:人速激肽受体2/NK2R)

Anti-Human TACR2 Polyclonal Antibody|抗人TACR2多克隆抗体(靶标:人速激肽受体2/NK2R)

  • 货号:RB9THB728034
  • 价格:面议
  • 点击:473

产品介绍

产品参数

形态Liquid
宿主种属Rabbit
克隆性Polyclonal
抗体亚型IgG
纯化方式Purified by antigen affinity column.
内毒素水平Please contact with the lab for this information.
应用ELISA, IHC, WB
种属反应性Human
靶标NK-2 receptor, NK-2R, NK2R, NKNAR, Neurokinin A receptor, SKR, Substance-K receptor, TAC2R, TACR2, Tachykinin receptor 2
免疫原E. coli - derived recombinant Human TACR2 (Asn311-Asp362).
储存缓冲液0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
产品使用说明ELISA:1:5000-1:20000;IHC:1:50-1:500;WB:1:500-1:2000
登录号P21452
背景信息

Substance-K receptor (TACR2) is a ~44 kDa protein. This is a receptor for the tachykinin neuropeptide substance K (neurokinin A). Is also able to bind and respond to tachynins substance P and neurokinin B/neuromedin-K. The rank order of affinity of this receptor to tachykinins is: substance K > neuromedin-K > substance P. Substance K binding to its receptor triggers G protein-coupled receptor signaling via activation of G(q) and phosphatidylinositol hydrolysis by phospholipase C. Substance K binding also triggers signaling via activation of adenylate cyclase activity which results in increased intracellular levels of cyclic AMP (cAMP).

1. Cyr, C. et al. (1991) Annals of the New York Academy of Sciences 632, 426-7. PMID: 1659297
2. Kris, RM. et al. (1991) Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research 2, 15-22. PMID: 1848773
3. Edgerton, MD. et al. (1994) FEBS letters 354, 195-9. PMID: 7957923
4. Sun, W. et al. (2022) Cell discovery 8, 72. PMID: 35882833
备注For research use only
【仅供科学研究使用】

相关产品:
产品名称 点击数
Anti-Ixekizumab Non-Neutralizing Recombinant Antibody |抗依奇珠单抗非中和重组抗体(靶标:依奇珠单抗非中和抗体) 301
Anti-Ixekizumab Non-Neutralizing Recombinant Antibody |抗依奇珠单抗非中和重组抗体(靶标:依奇珠单抗非中和抗体) 325
Anti-Ixekizumab Non-Neutralizing Recombinant Antibody |抗依奇珠单抗非中和重组抗体(靶标:依奇珠单抗非中和抗体) 497
Anti-Ixekizumab Neutralizing Recombinant Antibody |抗依奇珠单抗中和重组抗体(靶标:依奇珠单抗中和抗体) 482
Anti-Ixekizumab Neutralizing Recombinant Antibody |抗依奇珠单抗中和重组抗体(靶标:依奇珠单抗中和抗体) 412
Anti-Ixekizumab Neutralizing Recombinant Antibody |抗依奇珠单抗中和重组抗体(靶标:依奇珠单抗中和抗体) 376
Anti-Daratumumab Non-Neutralizing Recombinant Antibody|抗达雷妥尤单抗非中和重组抗体(靶标:达雷妥尤单抗非中和抗体) 433
Anti-Daratumumab Neutralizing Recombinant Antibody |抗达雷妥尤单抗中和重组抗体(靶标:达雷妥尤单抗中和抗体) 476
Anti-Daratumumab Neutralizing Recombinant Antibody |抗达雷妥尤单抗中和重组抗体(靶标:达雷妥尤单抗中和抗体) 434
Anti-Daratumumab Neutralizing Recombinant Antibody |抗达雷妥尤单抗中和重组抗体(靶标:达雷妥尤单抗中和抗体) 548
Anti-Daratumumab Neutralizing Recombinant Antibody |抗达雷妥尤单抗中和重组抗体(靶标:达雷妥尤单抗中和抗体) 505
Anti-Avelumab Non-Neutralizing Recombinant Antibody |抗阿维鲁单抗非中和重组抗体(靶标:阿维鲁单抗非中和抗体) 230
Anti-Avelumab Non-Neutralizing Recombinant Antibody |抗阿维鲁单抗非中和重组抗体(靶标:阿维鲁单抗非中和抗体) 296
Anti-Avelumab Non-Neutralizing Recombinant Antibody |抗阿维鲁单抗非中和重组抗体(靶标:阿维鲁单抗非中和抗体) 486
Anti-Avelumab Non-Neutralizing Recombinant Antibody |抗阿维鲁单抗非中和重组抗体(靶标:阿维鲁单抗非中和抗体) 306
Anti-Avelumab Neutralizing Recombinant Antibody |抗阿维鲁单抗中和重组抗体(靶标:阿维鲁单抗中和抗体) 498
Anti-Avelumab Neutralizing Recombinant Antibody |抗阿维鲁单抗中和重组抗体(靶标:阿维鲁单抗中和抗体) 295
Anti-Camrelizumab Neutralizing Recombinant Antibody |抗卡瑞利珠单抗中和重组抗体(靶标:卡瑞利珠单抗中和抗体) 561
Anti-Camrelizumab Neutralizing Recombinant Antibody |抗卡瑞利珠单抗中和重组抗体(靶标:卡瑞利珠单抗中和抗体) 525
Anti-Camrelizumab Neutralizing Recombinant Antibody |抗卡瑞利珠单抗中和重组抗体(靶标:卡瑞利珠单抗中和抗体) 452
总计 33037 个记录,共 1652 页,当前第 1648 页 | 第一页 上一页 下一页 最末页
在线客服
  • 销售热线:
  • 15898894496(同微信)
  • 我要留言
  • 周一至周五每天9:00-17:00